Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

PURPOSE: Somatic mutations and copy number variation in the ERBB family are frequent in urothelial carcinoma (UC) and may represent viable therapeutic targets. We studied whether afatinib (an oral, irreversible inhibitor of the ErbB family) has activity in UC and if specific ERBB molecular alteratio...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Choudhury, Noura J., Campanile, Alexa, Antic, Tatjana, Yap, Kai Lee, Fitzpatrick, Carrie A., Wade, James L., Karrison, Theodore, Stadler, Walter M., Nakamura, Yusuke, O’Donnell, Peter H.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2016
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569685/
https://ncbi.nlm.nih.gov/pubmed/27044931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.66.3047
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы